HIND on Nasdaq

Vyome Holdings, Inc

American pharmaceutical preparations company, incorporated in Delaware. Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with Allarity Therapeutics, Inc., Immuneering Corp or Edesa Biotech, Inc., or pick any stock.

  • TickerHIND on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersSan Clemente, California1
  • Incorporated inDE2
  • Business address1001 Calle Amanecer, San Clemente, Ca 926732
  • Filer category, Emerging growth company2

See how the biggest companies compare on our leaderboards

Merger Agreement, Merger Sub merged with and into Vyome, with Vyome surviving the merger as a subsidiary of the Company (the “Merger”).3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

68.4%Gross margin4
-3269.4%Operating margin4
-3209.7%Net margin4
-96.0%Revenue growth, 20254
-272.8%Return on equity4

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Product brought in 55% of the revenue Vyome Holdings, Inc broke down this way in fiscal 2025.

  1. Product$174.6K455%up 30% from 2024
  2. License$116.9K437%
  3. Royalty$28.2K49%down 41% from 2024
Products and services by year
Products and services20242025
Product$134.4K$174.6K
License$116.9K
Royalty$47.4K$28.2K

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue3¢$100.9K
  • Research and development19¢$588.3K
  • Selling, general and admin77¢$2.4M

Out of $319.7K in revenue.4 The company lost money this year.

Financial statements

Revenue567894$319.7K in 2025−90% since 2019
0$5.0M$10.0M$15.0M2019: $3.3M$3.3M20192020: $11.3M$11.3M2020+244%2021: $13.6M$13.6M2021+20%2022: $11.2M$11.2M2022−17%2023: $8.7M$8.7M2023−23%2024: $8.0M$8.0M2024−8%2025: $319.7K$319.7K2025−96%
Gross profit567894$218.8K in 2025−34% since 2019
0$2.5M$5.0M$7.5M$10.0M2019: $331.0K$331.0K20192020: $6.3M$6.3M2020+1792%2021: $8.3M$8.3M2021+33%2022: $6.8M$6.8M2022−19%2023: $5.5M$5.5M2023−18%2024: $195.0K$195.0K2024−96%2025: $218.8K$218.8K2025+12%
Operating income567894-$10.5M in 2025−55% since 2019
-$60.0M-$40.0M-$20.0M02019: -$23.2M-$23.2M20192020: -$12.5M-$12.5M2020−46%2021: -$57.9M-$57.9M2021+365%2022: -$46.4M-$46.4M2022−20%2023: -$15.4M-$15.4M2023−67%2024: -$1.0M-$1.0M2024−93%2025: -$10.5M-$10.5M2025+939%
Net income567894-$10.3M in 2025−57% since 2019
-$80.0M-$60.0M-$40.0M-$20.0M02019: -$23.7M-$23.7M20192020: -$21.6M-$21.6M2020−9%2021: -$63.1M-$63.1M2021+192%2022: -$46.2M-$46.2M2022−27%2023: -$11.4M-$11.4M2023−75%2024: -$1.4M-$1.4M2024−87%2025: -$10.3M-$10.3M2025+609%

Every line of the income statement as filed: the last 2 fiscal years, latest first.4

Period ending2025-12-312024-12-31
Revenue$319.7K$256.9K
Cost of goods sold-$100.9K-$62.0K
Gross profit$218.8K$195.0K
Depreciation and amortization$12.0K$17.3K
Selling, general and administrative$2.4M$898.6K
Research and development$588.3K$285.4K
Transactional fees$7.7M
Total operating expenses$10.7M$1.2M
Operating loss-$10.5M-$1.0M
Interest expense-$146.6K-$206.0K
Other income(loss), net$91.0K$3.8K
Fair value adjustment$30.5K-$238.9K
Total other income (expense), net-$25.1K-$441.1K
Net loss attributable to non-controlling interest-$215.7K
Net loss attributable to owners of Vyome Holdings, Inc.-$10.3M-$1.4M
Net loss-$10.5M-$1.4M
Foreign currency translation adjustments-$25.7K$1.1K
Total comprehensive loss-$10.5M-$1.4M
Loss per share basic (in Dollars per share)-$4.86-$6,001.39
Loss per share diluted (in Dollars per share)-$4.86-$6,001.39
Weighted average number of shares outstanding basic (in Shares)2.2M shares241 shares
Weighted average number of shares outstanding diluted (in Shares)2.2M shares241 shares

Compare Vyome Holdings, Inc with another company

Leadership

Who has led Vyome Holdings, Inc, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Andrew P. Rasdal2016–2020
  2. Kelly Huang2019
  3. William J. Plovanic2019–2020
  4. Barton P. Bandy2021–2022
  5. Paul F. Hickey2022
  6. Venkateswarlu Nelabhotla2025–now

Chair

  1. Andrew P. Rasdal2019–2020

President

  1. Andrew P. Rasdal2016–2020
  2. William J. Plovanic2019–2020
  3. Barton P. Bandy2021–2022
  4. Paul F. Hickey2022
  5. Venkateswarlu Nelabhotla2025–now

Chief financial officer

  1. William J. Plovanic2016–2019
  2. Nooshin Hussainy2019–2020
  3. Thomas Stankovich2021–2024
  4. Jerry Leonard2026–now

Chief operating officer

  1. Kelly Huang2017–2018
20202025
Board members and other officers (32)

Former names

  • ReShape Lifesciences Inc.Jun 22, 2021 to Aug 14, 20252
  • OBALON THERAPEUTICS INCFeb 13, 2008 to Jun 21, 20212

Timeline

  1. Sep 11, 2025New chief executive Venkateswarlu Nelabhotla becomes CEO12
  2. Aug 26, 2022New chief executive Paul F. Hickey becomes CEO13
  3. Sep 17, 2021New chief executive Barton P. Bandy becomes CEO14
  4. Oct 28, 2019New chief executive William J. Plovanic becomes CEO16
  5. Jan 4, 2019New chief executive Kelly Huang becomes CEO15
  6. Oct 5, 2016New chief executive Andrew P. Rasdal becomes CEO17

Filings

268 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 73 major events, 50 insider forms, 19 large holders, 106 other. The latest 20:

  1. Sep 3, 20264 EDGAR
  2. Sep 1, 20263 EDGAR
  3. Aug 28, 20268-K CURRENT REPORT EDGAR
  4. Aug 25, 20268-K CURRENT REPORT EDGAR
  5. Aug 12, 202610-Q QUARTERLY REPORT EDGAR
  6. May 29, 20268-K CURRENT REPORT EDGAR
  7. May 12, 202610-Q QUARTERLY REPORT EDGAR
  8. Apr 29, 20268-K CURRENT REPORT EDGAR
  9. Mar 31, 2026DEF 14A PROXY STATEMENT EDGAR
  10. Mar 20, 2026PRE 14A PRELIMINARY PROXY STATEMENT EDGAR
  11. Mar 18, 202610-K ANNUAL REPORT EDGAR
  12. Feb 25, 20268-K CURRENT REPORT EDGAR
  13. Feb 13, 20268-K CURRENT REPORT EDGAR
  14. Jan 28, 20268-K CURRENT REPORT EDGAR
  15. Dec 23, 20258-K CURRENT REPORT EDGAR
  16. Nov 26, 2025424B3 PROSPECTUS EDGAR
  17. Nov 19, 20258-K CURRENT REPORT EDGAR
  18. Nov 19, 20254 OWNERSHIP DOCUMENT EDGAR
  19. Nov 19, 20253 OWNERSHIP DOCUMENT EDGAR
  20. Nov 18, 20254 OWNERSHIP DOCUMENT EDGAR

The 268 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

46 open-market trades by officers, directors and large owners since October 2021: 3 buys and 43 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
May 31, 2024STANKOVICH THOMASChief Financial OfficerSale48$0.25$12Form 4
Feb 29, 2024STANKOVICH THOMASChief Financial OfficerSale43$0.17$7Form 4
Dec 31, 2023STANKOVICH THOMASChief Financial OfficerSale42$0.25$10Form 4
Nov 30, 2023STANKOVICH THOMASChief Financial OfficerSale39$0.23$9Form 4
Oct 25, 2023STANKOVICH THOMASChief Financial OfficerSale131$0.27$35Form 4
Oct 11, 2023STANKOVICH THOMASChief Financial OfficerSale39$0.93$36Form 4
Sep 1, 2023STANKOVICH THOMASChief Financial OfficerSale118$0.89$105Form 4
Aug 24, 2023STANKOVICH THOMASChief Financial OfficerSale39$1.42$55Form 4
Aug 4, 2023STANKOVICH THOMASChief Financial OfficerSale108$1.43$154Form 4
Jul 6, 2023STANKOVICH THOMASChief Financial OfficerSale106$1.47$156Form 4
Jun 30, 2023STANKOVICH THOMASChief Financial OfficerBuy17,702$1.52$26.9KForm 4
May 31, 2023STANKOVICH THOMASChief Financial OfficerSale98$2.41$236Form 4
Apr 30, 2023STANKOVICH THOMASChief Financial OfficerSale96$2.36$227Form 4
Mar 31, 2023STANKOVICH THOMASChief Financial OfficerSale109$2.60$283Form 4
Feb 28, 2023STANKOVICH THOMASChief Financial OfficerSale103$4.25$438Form 4
Feb 2, 2023STANKOVICH THOMASChief Financial OfficerSale157$13.29$2.1KForm 4
Jan 24, 2023STANKOVICH THOMASChief Financial OfficerSale158$7.49$1.2KForm 4
Dec 1, 2022STANKOVICH THOMASChief Financial OfficerSale7,357$0.15$1.1KForm 4
Nov 28, 2022STANKOVICH THOMASChief Financial OfficerSale364,756$0.17$62.0KForm 4
Nov 4, 2022STANKOVICH THOMASChief Financial OfficerSale8,393$0.27$2.3KForm 4

All 46 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Citadel Advisors LLC25,972$55.8K0.0%New
Geode Capital Management, LLC25,793$55.5K0.0%No change
Focus Partners Wealth14,640$31.5K0.0%No change
Vanguard Fiduciary Trust Co12,195$26.2K0.0%No change
UBS Group AG11,908$25.6K0.0%−10,767
Susquehanna International Group, Llp10,058$21.6K0.0%New
Vanguard Capital Management LLC9,463$20.3K0.0%No change
Royal Bank Of Canada5,856$13.0K0.0%No change
Tower Research Capital LLC (TRC)1,808$3.9K0.0%+417
Barclays PLC26$560.0%New
Hrt Financial LP20,318$430.0%New
Caitong International Asset Management Co., Ltd3$60.0%+1

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62